Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jankiben R. Patel"'
Autor:
Jankiben R. Patel, Bipika Banjara, Afia Ohemeng, A. Michael Davidson, Stephen M. Boué, Matthew E. Burow, Syreeta L. Tilghman
Publikováno v:
Nutrients, Vol 15, Iss 7, p 1632 (2023)
As breast cancer cells transition from letrozole-sensitive to letrozole-resistant, they over-express epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), and human epidermal growth factor receptor 2 (HER2) while acquiring
Externí odkaz:
https://doaj.org/article/ad30942ba52a48da8d4a56ee5cf8f556
Autor:
Karen M. Gallegos, Jankiben R. Patel, Shawn D. Llopis, Rashidra R. Walker, A. Michael Davidson, Wensheng Zhang, Kun Zhang, Syreeta L. Tilghman
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Development of aromatase inhibitor resistant breast cancer among postmenopausal women continues to be a major clinical obstacle. Previously, our group demonstrated that as breast cancer cells transition from hormone-dependent to hormone-independent,
Externí odkaz:
https://doaj.org/article/76c502a5c9b24beeb41aa1ed18bdf8ce
Autor:
Jankiben R. Patel, Prasad Thangavelu, Renee M. Terrell, Bridg’ette Israel, Arindam Basu Sarkar, A. Michael Davidson, Kun Zhang, Rahul Khupse, Syreeta L. Tilghman
Publikováno v:
Biomolecules, Vol 12, Iss 4, p 531 (2022)
While Polo-like kinase 1 (PLK1) inhibitors have shown promise in clinical settings for treating triple-negative breast cancer tumors and other solid tumors, they are limited by their ability to bind non-selectively to the ATP kinase domain. Therefore
Externí odkaz:
https://doaj.org/article/3796a2477f224d1299a65bc797b79b26
Autor:
Rashidra R. Walker, Jankiben R. Patel, Akash Gupta, A. Michael Davidson, Christopher C. Williams, Florastina Payton-Stewart, Stephen M. Boué, Matthew E. Burow, Rahul Khupse, Syreeta L. Tilghman
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 5, p 2887 (2022)
Aromatase inhibitors (AIs) are standard treatment for estrogen-dependent postmenopausal breast tumors; however, resistance develops leading to tumor relapse and metastasis. We previously demonstrated that glyceollin inhibits proliferation, survival,
Externí odkaz:
https://doaj.org/article/04736aedd1034674a5167acfeda47bb6
Autor:
Akash Gupta, Geetanjali Gupta, Rajeshwari R. Mehta, David Z. Ivancic, Rashidra R. Walker, Jankiben R. Patel, Karen M. Gallegos, A. Michael Davidson, Seema A. Khan, Rajendra G. Mehta, Syreeta L. Tilghman
Publikováno v:
Biology Open, Vol 9, Iss 5 (2020)
Mouse mammary organ culture (MMOC) is used to evaluate the efficacy of chemopreventive agents against the development of carcinogen-induced preneoplastic lesions and is highly correlative to in vivo carcinogenesis models. Here, we developed a new ex
Externí odkaz:
https://doaj.org/article/70b70488c5114928ae7740456db4128d
Publikováno v:
Cancer Research. 83:406-406
As breast cancer cells transition from letrozole-sensitive to letrozole resistance they over-express EGFR, MAPK, and HER2 and acquire enhanced motility and EMT-like characteristics that are attenuated and reversed by glyceollin treatment, respectivel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1e6449bd2054511038064574360c3bd
https://doi.org/10.1158/1538-7445.am2023-406
https://doi.org/10.1158/1538-7445.am2023-406
Autor:
Syreeta L. Tilghman, A. Michael Davidson, Karen M. Gallegos, Jankiben R. Patel, Rashidra R. Walker
Publikováno v:
Cancer Research. 80:P3-11
Aromatase inhibitors (AIs) are currently the standard treatment for postmenopausal women with estrogen-dependent metastatic breast cancer. While effective, patients develop resistance leading to tumor relapse, metastasis, and more aggressive phenotyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a8c068c62eaeedb4a5a119fc860164a
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-15
https://doi.org/10.1158/1538-7445.sabcs19-p3-11-15
Autor:
A. Michael Davidson, Syreeta L. Tilghman, Karen M. Gallegos, Jankiben R. Patel, Ian Davenport, Rashidra R. Walker
Publikováno v:
Oncol Lett
Aromatase inhibitors (AIs), such as letrozole, are considered as first-line treatment for estrogen receptor-positive breast cancer in postmenopausal women. Despite the successful use of letrozole, resistance to therapy, tumor relapse and metastasis r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4378091d2a73c7c5057caa0d97c56eba
https://pubmed.ncbi.nlm.nih.gov/34267813
https://pubmed.ncbi.nlm.nih.gov/34267813
Publikováno v:
Cancer Research. 80:4116-4116
Aromatase inhibitors (AIs) are the standard endocrine treatment for postmenopausal women with estrogen-dependent metastatic breast cancer. While effective, some patients develop resistance leading to tumor relapse, metastasis, and more aggressive phe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93bf49a68d9d1056f50712faecc0e58e
https://doi.org/10.1158/1538-7445.am2020-4116
https://doi.org/10.1158/1538-7445.am2020-4116
Autor:
Karen M. Gallegos, Jankiben R. Patel, A. Michael Davidson, Syreeta L. Tilghman, Rashidra R. Walker, Ian Davenport
Publikováno v:
Cancer Research. 80:3794-3794
Aromatase inhibitors (AI), like letrozole, are the first-line treatment for ER+ breast cancer in post-menopausal women. Despite widespread successful usage of letrozole, resistance to therapy, tumor relapse, and metastasis remain the principal causes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::862cc08894b1a4c6f41118959397cc3c
https://doi.org/10.1158/1538-7445.am2020-3794
https://doi.org/10.1158/1538-7445.am2020-3794